Biotech Company’s Testing Solution Wants to Get People Back to Work
Boston-based biotech company Meenta recently launched a comprehensive COVID-19 testing solution to create the first complete return-to-work program in the United States. Its proprietary surveillance testing model lets manufacturers and distributors proactively monitor and test a fraction of their staff, resulting in an 80 to 90% savings in testing costs.
Pepin Distributing, one of the largest Anheuser-Busch distributors in the country, signed on to gain access to Meenta’s network of labs. This gives the company the ability to conduct on-demand workplace testing and get results back in 24 to 48 hours. Meenta said its “return to work, data-driven testing platform gives Pepin everything they need to create a safe and controlled workplace environment for employees.”
Meenta’s COVID-19 testing program is based on its online platform and provides access to many types of sample collection kits, including viral and antibody tests. It has a capacity to perform 500,000 tests per week throughout its 100 FDA-certified clinical labs.